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Abstract
Background: Fibre type specification is a poorly understood process beginning in embryogenesis
in which skeletal muscle myotubes switch myosin-type to establish fast, slow and mixed fibre
muscle groups with distinct function. Growth factors are required to establish slow fibres; it is
unknown how fast twitch fibres are specified. Igf-2 is an embryonically expressed growth factor
with established in vitro roles in skeletal muscle. Its localisation and role in embryonic muscle
differentiation had not been established.
Results: Between E11.5 and E15.5 fast Myosin (FMyHC) localises to secondary myotubes evenly
distributed throughout the embryonic musculature and gradually increasing in number so that by
E15.5 around half contain FMyHC. The Igf-2 pattern closely correlates with FMyHC from E13.5 and
peaks at E15.5 when over 90% of FMyHC+ myotubes also contain Igf-2. Igf-2 lags FMyHC and it is
absent from muscle myotubes until E13.5. Igf-2 strongly down-regulates by E17.5. A striking feature
of the FMyHC pattern is its increased heterogeneity and attenuation in many fibres from E15.5 to
day one after birth (P1). Transgenic mice (MIG) which express Igf-2 in all of their myotubes, have
increased FMyHC staining, a higher proportion of FMyHC+ myotubes and loose their FMyHC
staining heterogeneity. In Igf-2 deficient mice (MatDi) FMyHC+ myotubes are reduced to 60% of
WT by E15.5. In vitro, MIG induces a 50% excess of FMyHC+ and a 30% reduction of SMHyC+
myotubes in C2 cells which can be reversed by Igf-2-targeted ShRNA resulting in 50% reduction of
FMyHC. Total number of myotubes was not affected.
Conclusion: In WT embryos the appearance of Igf-2 in embryonic myotubes lags FMyHC, but by
E15.5 around 45% of secondary myotubes contain both proteins. Forced expression of Igf-2 into
all myotubes causes an excess, and absence of Igf-2 suppresses, the FMyHC+ myotube component
in both embryonic muscle and differentiated myoblasts. Igf-2 is thus required, not for initiating
secondary myotube differentiation, but for establishing the correct proportion of FMyHC+
myotubes during fibre type specification (E15.5 - P1). Since specific loss of FMyHC fibres is
associated with many skeletal muscle pathologies these data have important medical implications.
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In mouse, skeletal muscle fibres are formed during the
second half of embryogenesis (E11.5–E16.5). The dorsal
epaxial muscles and the proximal and distal (hypaxial)
muscles are thought to derive respectively from two dis-
tinct groups of myogenic precursors (stem cells) which
originate in the somites [1]. Both groups of cells subse-
quently undergo two overlapping waves of differentiation
which form respectively, the primary and secondary myo-
tubes. In primary myogenesis (E9.5–E13.5) a scaffold of
short, fat primary myotubes is established [2]. Secondary
myogenesis, in which a larger number of long, thin sec-
ondary myotubes is formed around the primary scaffold,
is initiated around E11.5 and continues into early post-
natal life [3]. Primary and secondary myotubes can be dis-
tinguished by their morphology, their location and by the
skeletal myosin sub-types that they produce. In cross-sec-
tion, it can be seen that a number of smaller diameter sec-
ondary myotubes form in clusters around a single large
diameter primary myotube [3]. Whilst both primary and
secondary myotubes are reported to make development
specific (foetal, embryonic and neonatal) myosins, new
primary myotubes also express slow myosin whilst newly
formed secondary myotubes initially express fast myosin
[2,3]. Towards the end of secondary myogenesis 'fibre-
type switching' takes place in which some primary myo-
tubes become fast-myosin positive and some secondary
myotubes switch to slow myosin [4,5]. This process is
thought to establish discrete muscle groups with distinct
function dependent upon a unique combination of fibres
expressing fast (Type 2a, b and x) and slow (Type 1)
myosin heavy chain (MyHC) forms and is essential for
normal post-natal functioning of the skeletal muscula-
ture. Further refinement of MyHC and Myosin light chain
(MyLC) expression occurs perinatally and during subse-
quent post-natal growth [6,7]. Mature adult mammalian
skeletal muscles are uniquely defined by their particular
composition of fast and slow fibre types and may express
single MyHC or a mixture of several MyHC. Additional
complexity is conferred by the MyLC [8].
A host of growth factors are required to establish and dif-
ferentiate embryonic skeletal muscle myotubes, but very
little is known about the process of fibre type switching in
development. In the zebra fish embryo it has been dem-
onstrated, that two growth factors; Hepatocyte growth fac-
tor and Myostatin play roles respectively in somitogenesis
and in the establishment of the hypaxial lineage [9,10]. In
mouse, several families of growth factor (Wnt, Shh and
BMP) have been shown to play a role in establishing skel-
etal muscle lineage; whilst others (Notch, FGF family,
antagonists of Wnt signalling (sFRP1, 2, 4)) play roles in
maintaining, promoting or restricting skeletal muscle
embryonic differentiation [11]. Commitment to the skel-
etal muscle lineage is reported to require the suppression
of BMP4 [12]. In the chick embryo somite differentiation
can be induced experimentally by several growth factors
including Shh, FGF-2 and TGF-β which, in this system, act
synergistically with Igf-2, Igf-1 or insulin to augment skel-
etal muscle differentiation although fibre type was not
investigated in this study [13].
There is currently little genetic data available on the estab-
lishment of fibre type per se; however two lines of evi-
dence suggest that this is also regulated by growth factor
action. In zebra fish embryos, generation of the slow mus-
cle fibres is dependent on Sonic hedgehog (Shh); whilst in
chick limb Shh promotes slow fibre differentiation
[14,15]. In mouse however Shh is associated with estab-
lishing the epaxial lineage and has not been shown to
influence fibre-type selection [16]. Recently it was shown
that embryonic loss of FGF-6 in the mouse results in ear-
lier myotube formation and a skewing of fibre-type com-
position towards Type 1 (slow fibres) suggesting that FGF-
6 may have an inhibitory effect on type 1 fibre differenti-
ation [17]. With the exception of our data reported here,
there are no other data on genetic regulation of fibre-type
selection during embryonic myogenesis.
The growth factor Igf-2 can regulate differentiation in cul-
tured skeletal muscle cells [18] and in chick somite
explants [13], whilst androgenetic (paternal disomy)
embryos and embryonic stem cells that over-express Igf-2
display preferential differentiation into skeletal muscle
[19]. In mammals Igf-2 is reported to promote mesoderm
differentiation [20]. In rodents, Igf-2 is primarily an
embryonic growth factor, widely expressed throughout
embryogenesis, but substantially down-regulated at birth
[21]. The closely related peptide growth factor, Igf-1 has
an embryonic expression pattern distinct from Igf-2 which
is associated with the developing nervous system and
undifferentiated mesenchyme [22-24]. Surprisingly, the
protein localisation pattern for Igf-2 has not previously
been established.
To establish a role for Igf-2 in fibre type specification dur-
ing mammalian myogenesis we first established its precise
localisation pattern in embryonic myotubes in relation to
FMHyC. We showed that Igf-2 is present in 50% of embry-
onic myotubes at E15.5. To test the functional importance
of Igf-2 localisation to particular myotubes we used a
muscle targeted promoter (muscle Creatine Kinase, mCK)
to force over-expression of Igf-2 in all embryonic myo-
tubes in order to disrupt FMyHC myotube formation in
these (MIG) mice. Conversely, we used Igf-2 deficient
mice to establish the fate of FMyHC positive myotubes in
the absence of Igf-2. By combining ShRNA interference
with the MIG transgene we show that Igf-2 has a substan-
tial impact on the generation of fast and slow MyHC con-
taining myotubes in vitro. Fast myosin fibre-typePage 2 of 16
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with important medical applications. The fast fibre-type
ratio is perturbed in a number of myopathies and skeletal
muscle dystrophies, whilst disproportionate fast myosin
fibre degeneration is associated with skeletal muscle age-
ing [25,26]. Previously we have shown Igf-2 to ameliorate
the dystrophic phenotype [27]. The data presented here
suggest a new function for Igf-2 in the specification of this
crucial muscle fibre subset.
Results
Immunostaining reveals a dynamic and tightly linked 
localisation pattern between Igf-2 and fast myosin during 
secondary embryogenesis
Embryonic skeletal muscles containing differentiated
myotubes are first evident in mouse from around E11.5
(Fig. 1A–D). At E11.5 embryonic myotubes can be readily
distinguished by their immunoreactivity to the pan-
myosin antibody MF20 (Fig. 1A, E), whilst large numbers
of Pax 7 staining skeletal muscle precursor cells delineate
these newly forming muscle groups (Fig. 1B, F). Fast-
myosin (FMyHC) is first detected by My32 antibody in a
small number of secondary myotubes at E11.5 although
Igf-2 cannot be detected in skeletal muscle myotubes at
this stage (Fig. 1C–D, G–H). When proteins are separated
on 7.5% acrylamide gels all three FMyHC isoforms (type
2a, 2x and 2b) are detected, low levels of neonatal myosin
are also present, running coincident with the 2a band, but
which do not increase with embryonic stage suggesting
that the predominant isoforms detected by My32 from
E12.5 are the three adult FMyHC (Fig. 2(C–D)). Whole
embryo immunoblotting shows a rapid increase in the
amount of FMyHC present in mouse embryos between
E11.5 and E17.5 (Fig. 1I). This is reflected in the immu-
nostaining pattern for fast myosin between E13.5 to E15.5
where there is a large and rapid increase in the number of
FMyHC positive secondary myotubes in all embryonic
muscle groups during these stages. Figure 1(J–Z) illus-
trates the dynamic staining pattern of fast myosin and Igf-
2 in muscles of the forelimb at E13.5, E15.5, E17.5 and
just after birth (P1).
In skeletal muscle, Igf-2 is first detected in a small number
of myotubes at E13.5 in some, but not all, muscle groups
(Fig. 1J–L). Specificity of the Igf-2 antibody is shown in
Fig. 2(A–B). At this stage the localisation of fast MyHC is
considerably more extensive than that of Igf-2 with a
majority of secondary myotubes staining positively for
fast myosin (Fig. 1K–M). Igf-2 positive myotubes at this
stage were predominantly secondary myotubes which
also contained fast myosin (Fig. 1L, M indicated by
arrows). By E14.5 FMyHC is widely localised to secondary
myotubes throughout the skeletal musculature of the
embryo including in the muscles of the facial and distal
limb which differentiate later than the central core and
Immunostaining pattern of fast myosin and Igf-2 in the wild type (C57BL10) mouse embryoFigure 1
Immunostaining pattern of fast myosin and Igf-2 in the wild type 
(C57BL10) mouse embryo. (A, E) Pan-myosin (MF20) staining and (B, F) 
Pax 7 respectively, show the location of differentiated myotubes and undif-
ferentiated myoblasts at E11.5 in intercostal (ic), limb (l), trunk muscles (t) 
and upper proximal limb muscles (pr); (C, G) Igf-2 is absent from E11.5 
embryonic myotubes, (D, H) a small number of secondary myotubes stain 
with My32 (fast MyHC). (I) Immunoblot of whole embryo protein (E11.5 
to E17.5) showing fast MyHC (My32), Igf-2 and tubulin. FMyHC increases 
with stage. Igf-2 peaks at E15.5 and is downregulated in muscle at E17.5. 
Igf-2 is also present in non-muscle tissues (including liver, kidney, heart, 
gut) between E11.5 and E17.5. (J-M, O-Z) Imunostaining pattern of Igf-2 
and FMyHC in upper proximal limb muscles. (J-L) E13.5 embryos show an 
overlapping pattern of Igf-2 (J, L) and fast myosin (K, M) in secondary myo-
tubes. Enlarged areas (L, M) show secondary myotubes containing both Igf-
2 and fast myosin (indicated by white arrows). (N-R) At E15.5 Igf-2 and 
fast Myosin are localised to ~half of myotubes and show a strikingly similar 
pattern. (N-O) White arrows, double positive myotubes. Black arrows 
FMyHC positive, Igf-2 negative muscle group. (Q-R) most Igf-2 positive 
myotubes also stain for FMyHC (Black arrows, double positive myotubes). 
(N) Igf-2 mRNA is expressed predominantly in secondary myotubes 
broadly coincident (O) with the Igf-2 and (P) fast Myosin protein localisa-
tion patterns. (S-V) At E17.5 Igf-2 staining (S, U) is almost undetectable. 
Fast Myosin (T, V) staining shows increased heterogeneity compared to 
earlier stages (black arrows, reduced FMyHC staining). Skeletal muscles of 
day 1 pups (P1) contain (W, Y) no Igf-2 and (X, Z) have reduced and het-
erogenous fast Myosin staining (X, Z). (S-T, W-X) intercostals (ic); U-V, Y-
Z upper proximal (del, deltoid) muscles. Images shown in A-D (E-H); J-K 
(L-M); O-P (Q-R); S, T and U, V; W, X and Y-Z are adjacent sections. 
Immunostaining patterns were confirmed by at least three different runs 
on separate embryos (many more for the Igf-2 pattern) per stage. Images 
shown are fully representative of each run. Comparison of FMyHC, Igf-2, 
Pax 7 and MF20 was achieved by staining separate adjacent sections for 
each antibody in the same run. Negative second antibody controls were 
included in each run. Peptide absorption was carried out at each stage for 
the Igf-2 pattern. Magnification bars indicate 10 μC on all images.Page 3 of 16
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positive (Igf-2 and fast-myosin) myotubes increases sub-
stantially in embryonic muscles, as does the intensity of
staining for both proteins (data not shown). By E15.5
both FMyHC and Igf-2 are widely localised to secondary
myotubes throughout the embryonic musculature and
this pattern is largely coincident with the mRNA expres-
sion pattern in skeletal muscle at the same stage (Fig. 1N–
P). Careful matching of adjacent sections stained respec-
tively with Igf-2 and fast MyHC demonstrates that the Igf-
2 staining pattern is largely coincident in secondary myo-
tubes with that for fast myosin at E15.5 (Fig. 1Q–R, indi-
cated by arrows). Thus by E15.5 just under half of all
myotubes stain positively for fast myosin (47 ± 2.5 for
diaphragm) and a majority (>90%) of these also stain
positively for Igf-2 (44 ± 0.3 for diaphragm). Both primary
and secondary myotubes containing Igf-2 and FMyHC are
seen at this stage (Fig. 1Q, R, indicated by arrows). At
E15.5 a majority of embryonic skeletal muscles contain
FMyHC and most of these also contain comparable num-
bers of Igf-2 positive myotubes. A small number of mus-
cles contain FMyHC but very little Igf-2 staining (Fig. 1O–
P, indicated by arrows), these may be muscles destined to
become predominantly slow (oxidative) muscles. Very
rarely (<1% of myotubes) Igf-2 but not FMyHC staining
was seen. The proportion of FMyHC positive fibres in any
particular muscle group appears to be stable (see also Fig.
5). By E17.5 there is a sharp decline in the intensity of Igf-
2 staining in the majority of embryonic myotubes and an
increased heterogeneity in staining intensity of fast
myosin positive fibres (Fig. 1S–V). Whole embryo immu-
noblotting demonstrates a substantial increase in staining
for Igf-2 at E13.5 and E15.5 which is reduced at E17.5
reflecting this dynamic staining pattern for Igf-2 in skele-
tal muscle myotubes (Figure 1I). Igf-2 is also present in
non-muscle tissues (including liver, kidney, heart, gut)
between E11.5 and E17.5 (Figure 1I; Figure 2A–B). By P1
(day one post birth) both fast-myosin and Igf-2 are absent
from a majority of muscle fibres (Fig. 1W–Z). Thus both
Igf-2 and fast myosin display a dynamic staining pattern
during secondary myogenesis in which both proteins are
widely localised to secondary myotubes peaking in inten-
sity around E15.5. The Igf-2 pattern is more narrowly
defined, beginning later (E13.5) and declining earlier
(E17.5), than that of FMyHC suggesting that Igf-2 plays a
specific role during the growth (myotube expansion) and
maturation phases of late secondary myogenesis rather
than in the initiation of secondary myotubes..
Forced over-expression of Igf-2 in myotubes induces the 
generation of fast twitch muscle fibres
To further establish the role of Igf-2 in fast twitch muscle
fibre formation we generated clonal skeletal muscle cell
lines which specifically over-express Igf-2 in differentiated
myotubes. To achieve this we used a bicistronic transgene
(MIG) which conditionally drives the independent
expression of Igf-2 and GFP in differentiated myotubes
under the control of the full length muscle creatine kinase
promoter (p3300mCK). The p3300mCK is activated dur-
ing myotube differentiation and is expressed in all fully
differentiated myotubes but not in undifferentiated
Antibody specificity; (A) Igf-2 immunostaining of adjacent sections of an e13Figure 2
Antibody specificity; (A) Igf-2 immunostaining of adjacent 
sections of an e13.5 embryo illustrate positive Igf-2 staining 
(brown) in liver (liv) and diaphragm (dia) which, (B) is com-
pletely abolished by pre-incubation of the antibody with 2ug/
ml Igf-2 (pep; peptide absorption) demonstrating the specifi-
city of Igf-2 staining. (C-D) Immunoblotting of whole embryo 
protein (E12.5 – E17.5) with, (C) clone My32 anti-FMyHC 
antibody: detects three positive bands corresponding to the 
three isoforms of adult fast myosin heavy chain (FMyHC) 2b, 
2a and 2x/d. E12.5 and E13.5 tracks contain 20 μg protein. 
E15.5 and E17.5 tracks are loaded with 10 μg protein to pre-
vent over-exposure of FMyHC, this is reflected in the inten-
sity of bands in the anti-Spectrin loading control. (D) Because 
My32 is reported to cross-react with neonatal MyHC in rat 
we compared My32 staining with an anti-neonatal MyHC 
antibody (clone WB-MHCn) which detects a weak band cor-
responding to neonatal MyHC and coincident with FMyHC 
2b. We conclude that the predominant FMyHC forms 
detected by My32 in mouse embryos are therefore Adult 
FMyHC 2a, 2x and 2b. WB-MHCn weakly cross-reacts with 
the adult fast myosin marker (track M).Page 4 of 16
(page number not for citation purposes)
BMC Developmental Biology 2007, 7:65 http://www.biomedcentral.com/1471-213X/7/65myoblasts [28]. Clonally derived, MG, cells which express
GFP but not Igf-2 under the control of the pmCK were
used as a control. Cell lines were generated by transfecting
MG or MIG respectively into C2C12 cells followed by
clonal derivation of picked colonies by serial dilution.
Plating efficiency and colony formation assays carried out
on C2MG (B9) and C2MIG (H19) cells showed no signif-
icant difference between the two lines (Student t test: p =
0.23 and p = 0.60 respectively). Consistent with the
reported expression pattern, neither GFP nor IGF-2 is
present in proliferating, undifferentiated C2MIG cells
whilst C2MIG myotubes express both proteins (Fig. 3A–
B). The timing of GFP expression in C2MG cells is compa-
rable to that of C2MIG (not shown). In high density cul-
tures, C2MG (and other wild-type) myoblast cell lines,
undergo sporadic spontaneous differentiation to form
myotubes but only a minority of these myotubes express
fast MyHC (black arrows, white arrows indicate FMyHC
negative myotubes) (Fig. 3C). Spontaneously differentiat-
ing high density cultures of C2MIG expressing cells on the
other hand, have a substantially increased proportion of
FMyHC positive myotubes and increased FMyHC protein
suggesting that the presence of Igf-2 in these myotubes
increases the likelihood of fast MyHC expression in the
resultant myotubes (Fig. 3D–E).
When C2MIG and C2MG cells are placed at lower culture
densities under differentiation permissive conditions
(low serum, 2% horse serum) both will differentiate
extensively after 3 days. Whilst there is no difference
between the total number of myotubes generated by the
two cell lines after 3 days there is a striking (and statisti-
cally highly significant) difference in the proportion of
fast and slow MyHC positive myotubes generated by the
two cell lines (Fig. 3F). C2MIG expressing cells consist-
ently generate 30% more fast MyHC positive myotubes
(59.8 ± 2.9 %) than do C2MG (39.3 ± 4.8 %) and a 30%
reduction in the proportion of slow (Type 1) MyHC posi-
tive fibres (Fig. 3F). Western blotting confirms the
increased expression of fast MyHC in differentiated
C2MIG compared to C2MG myoblasts (Fig. 3F). These
data clearly demonstrate that over-expression of Igf-2 in
mouse skeletal myotubes promotes fast MyHC positive
myotube formation; the concomitant reduction in slow
MyHC positive fibres suggests that it may induce some
myotubes to switch from slow to fast MyHC.
Mice carrying the MG transgene display strong GFP
expression in their skeletal muscle myotubes at E17.5 and
P1 and like wild type, contain very little Igf-2 in their myo-
tubes at E17.5 and during early postnatal life. MIG mice
on the other hand, exhibit labelling of both Igf-2 and GFP
in their myotubes in late gestation (E17.5) and the early
postnatal period (Fig. 4A). Immunostaining for FMyHC
demonstrates a substantial increase in staining intensity
Differentiated C2MIG myotubes, but not undifferentiated myoblas s, show (A) strong immunostaining (brow ) for IGF-2, (Counterstain is Hae atoxylin (blue)) a d (B) bright green fluorescenc  (GFP)Figure 3
Differentiated C2MIG myotubes, but not undifferentiated myoblasts, 
show (A) strong immunostaining (brown) for IGF-2, (Counterstain is 
Haematoxylin (blue)) and (B) bright green fluorescence (GFP). DAPI 
counterstained nuclei (blue) reveal that undifferentiated cells do not 
express the GFP transgene. Spontaneous differentiation into fast 
MyHC positive myotubes occurred (C) rarely in C2MG (B9) cells but 
more frequently (D) in C2MIG (H19) cells cultured under non-per-
missive conditions (DMF12 and 10% FCS) for 5 days. A majority of 
C2MG (B9) and a minority of C2MIG (H19) myotubes formed are fast 
MyHC antibody negative (C-D; white arrows). A minority of C2MG 
myotubes and a majority of C2MIG myotubes, are FMyHC positive 
(C-D; Black arrows). Total myotube numbers: MG, 16.4 ± 3.2; MIG 
19.1 ± 3.5 ; Students t-test, p = 0.76. The average number of nuclei 
(per myotube) was 5.48 ± 1.17 (s.d.). (E) Immunoblotting shows a sub-
stantial increase in FMyHC in C2MIG compared to C2MG under 
these conditions. (F) After 3 days in differentiation permissive media 
there was a 50% increase (*, p = 0.003) in the proportion of FMyHC 
positive myotubes in C2MIG (H19) cells compared to C2MG (B9) and 
a concomitant 30% reduction (p = 0.05) in the proportion of SMyHC 
positive myotubes in C2MIG (H19) compared to C2MG (B9). Total 
myotube number was not altered (p = 0.47). Graph shows the mean 
and standard deviation of 3 separate experiments, each performed in 
duplicate. Immunoblot shows the increase in FMyHC in C2MIG com-
pared to C2MG under the same regime. (G) E17.5 MIG embryos 
show a very strong generalised up-regulation of FMyHC in all skeletal 
muscles. (H) In MIG intercostals muscles almost all myotubes have 
intense FMyHC staining compared to (I) MG embryos at E17.5. (J) A 
probe recognising the intersection between the pmCK and Igf-2 was 
used to genotype MIG transgenic positive (track 4) and MIG transgene 
negative (track 3) mice. Track 1, MG and track 2, MIG plasmid PCR, 
demonstrate the specificity of the MIG PCR primers. M - 1Kb ladder. 
PCR to genotype MIG transgene positive (track 4) and MIG transgene 
negative (track 3) mice. Primer set mCKIgf-2 1. Data shown is of one 
MIG+ and one MG+ E17.5 embryo. The phenotype is representative 
of 3 other E17.5 MIG+ embryos immunostained for FMyHC. 2 MG+ 
E17.5 embryos and 4 E17.5 MIG- littermates showed an identical 
FMyHC phenotype to WT C57BL10 E17.5 embryos (Figure 3I and 
Figure 1).Page 5 of 16
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the skeletal muscles of MIG at E17.5 which corresponds
with the increased levels of Igf-2 in the myotubes of these
embryos (Fig. 3G–H). MG embryos at this stage have a
level of FMyHC staining comparable to that seen in wild
type (Fig. 3I). The characterisation of MIG positive
embryos is shown in Fig. 3J. These data strongly support a
role for Igf-2 in the maintenance and regulation of
FMyHC in embryonic myotubes.
Over-expression of Igf-2 prevents down-regulation of fast-
myosin at birth in MIG+ mice
The down-regulation of fast-myosin in the skeletal mus-
cles of neonates is thought to be related to the process of
establishing mature skeletal muscle groups which is com-
pleted (in mice) during the first 1–2 weeks post birth. The
close correlation during myogenesis between the localisa-
tion patterns of Igf-2 and fast skeletal myosin (Fig. 1)
together with the excess production of fast MyHC contain-
ing myotubes when Igf-2 is over-expressed (Fig. 3) suggest
a role for Igf-2 in regulating this process. 4 MIG positive
pups were stained for FMyHC and all had a substantial
increase in the proportion of neonatal muscle fibres con-
taining fast MyHC compared to non-transgenic sibling
controls. The complete analysis of one representative
MIG+ pup is shown in (Figure 4B–I) compared to a wild
type sibling control which was processed in parallel (Fig.
1W–Z). Mice carrying the MIG transgene strongly express
both Igf-2 and Gfp in their skeletal muscles on day 1 of
birth (Fig. 4A). These mice also exhibit strong and exten-
sive FMyHC staining in all of their myofibres and
throughout their skeletal musculature (Fig. 4B, D, F, H).
Comparison with wild-type (non-transgenic) siblings
showed an extensive down-regulation of fast MyHC pro-
tein in the same muscles (Fig. 4C, E, G, I). Protein from
the hind part of this pup was subject to immunoblotting
and confirms a substantial increase in fast myosin heavy
and light chain proteins in MIG compared to sibling con-
trol muscles (Fig. 4J). Three other MIG+ pups also show
an increase in the FMyHC band compared to non-trans-
genic littermate controls (not shown). Detailed analysis of
individual muscles revealed that MIG muscles revealed
both an increase in the intensity of fast-myosin staining
compared to wild type as well as an increase in the propor-
tion of fibres retaining fast-myosin (Fig. 4K). This differ-
ence is most striking in muscle groups such as the Deltoid
and Trapezius destined to become mixed fibre muscles
(Fig. 4F–I, K). A shift towards fast myosin positive fibres
was also seen in the diaphragm and intercostal muscles
(Fig. 4B–E, K).
Loss of Igf-2 expression results in a substantial reduction in 
the proportion of fast-myosin positive myotubes in 
embryonic muscles
To establish a functional relationship between the gener-
ation of fast-twitch myotubes and Igf-2, we examined the
One day old pups (P1) carrying the MIG transgene exhibit, (A) GFP immunoreactivity in all of their skeletal muscle fibres and show up-regulation of fast-myosin in (B) intercostal, (D) Diaphramatic, (F) Trapezial d (H) Deltoidal mus les com-par d to (C, E, G, I) th  s me skel tal muscles in th ir nontran gen c litter m esFigur  4
One day old pups (P1) carrying the MIG transgene exhibit, 
(A) GFP immunoreactivity in all of their skeletal muscle fibres 
and show up-regulation of fast-myosin in (B) intercostal, (D) 
Diaphramatic, (F) Trapezial and (H) Deltoidal muscles com-
pared to (C, E, G, I) the same skeletal muscles in their non-
transgenic litter mates. (J) Immunostaining demonstrates that 
fast-myosin heavy chain (fast MyHC) is barely detectable at 
P1 in non-transgenic pups. Both fast MyHC and fast myosin 
light chain (MyLC) are substantially up-regulated in P1 MIG 
transgenic mice. (K) Comparison of the number of muscle 
fibres positively and negatively staining for fast-myosin shows 
an increase in the proportions of fast-myosin positive fibres 
in MIG transgenic muscles and a substantial shift from weak 
to strong staining in intercostal (IC), diaphragm (Dia), Trape-
zius (TpZ) and Deltoid (Del) muscles compared to non-
transgenic controls. Data shown is of one MIG+ P1 pup and a 
non-transgenic control. Three other pups analysed in the 
same way showed essentially the same phenotype. 2 MG P1 
pups had a phenotype indistinguishable from the WT litter-
mate. GFP (and Igf-2) immunostaining patterns in both MG 
and MIG were consistent with published expression patterns 
for mCK.Page 6 of 16
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skeletal muscles of a parental origin disomy mutant which
shows disruption of embryonic Igf-2 (and several genes
which regulate Igf-2 expression [29]). Maternal chromo-
some 7 disomy (MatDi) mutant mice show total loss of
their (paternal) monoallelic Igf-2 expression resulting in
an absence of skeletal muscle Igf-2 expression as well as
loss of circulating Igf-2 ([30]; Figure 5). We compared the
number, intensity of staining and localisation of fast
MyHC positive myotubes in MatDi mouse embryos at
E14.5 and E15.5 to those of their wild-type sibling con-
trols. At E14.5 the pattern of fast MyHc staining in MatDi
embryos is generally comparable to wild type except that
both the intensity of staining and the proportion of fast
MyHC containing myotubes is reduced (Fig. 5A). Interest-
ingly, FMyHC+ myotubes were not abolished despite the
complete suppression of Igf-2 protein (Figure 5B). Count-
ing the proportion of fast MyHC positive myotubes in a
range of different muscles (distal and proximal limb,
intercostal, diaphragm; trunk) reveals a consistent
decrease in the number of fast MyHC positive myotubes
in MatDi compared to WT at E14.5 and E15.5 (Fig. 5A;
Paired t-test: E14.5, p = 0.0601; E14.5, p = 0.03). At E15.5
there is a greater reduction in the number of fast MyHC
positive secondary myotubes over all muscles (compared
to E14.5) and there is still considerable heterogeneity
between muscle subgroups with the fast MyHC positive
myotube component ranging from being almost entirely
absent in some muscles (Fig. 5C), and up to half of wild
type numbers of fast MyHC + myotubes in other muscles
(Fig. 5E–F). In the respiratory muscles, FMyHC staining
was almost absent in MatDi intercostals compared to the
wild type in which around half of myotubes are FMyHC+
(Fig. 5C–D) whilst in the MatDi Diaphragm the number
of fast MyHC positive myotubes was around half that of
WT controls (Fig. 5E–F).
ShRNA Knockdown of Igf-2 reduces the proportion of fast-
myosin positive myotubes in differentiating muscle 
cultures
The data presented in the previous section showing a
reduction but not complete abolition of FMyHC+ myo-
tubes in the absence of Igf-2 (Fig. 5) show that Igf-2 is not
required for myotube induction and suggest that Igf-2
may be essential for the maintenance and maturation of
the fast twitch myotube component in embryonic mus-
cles in vivo rather than for their de novo synthesis. To test
this role for Igf-2 we used ShRNAi to knockdown Igf-2 in
differentiating myoblasts.
We used a shuttle vector (pShag1) to generate ShRNA con-
structs targeting GFP and Igf-2 (pShagGfp, pShagIgf-2
respectively) which knockdown their respective targets
with high efficiency. For details of these vectors see the
methodology section and [31]. Semi-quantitative RT-PCR
(A) The proportion of fast MyHC myotubes is decreased in Igf-2 d ficient mice (maternal diso y Chromosome 7 - MatDi) at E14Figure 5
(A) The proportion of fast MyHC myotubes is decreased in 
Igf-2 deficient mice (maternal disomy Chromosome 7 - 
MatDi) at E14.5 compared to WT sibling controls (Student t-
test, p = 0.06). By E15.5 there is an overall drop of 50% in the 
proportion of fast MyHC in MatDi embryos compared to 
WT (statistically significant by Student t-test, p = 0.03). (B) 
Embryo immunoblotting for Igf-2 demonstrates a stage 
related increase in Igf-2 protein between E10.5 and E15.5 in 
WT and absence of Igf-2 in MatDi embryos at E14.5 and 
E15.5 Tracks 1–4 E10.5, E13.5, E14.5 and E15.5 WT embryos 
respectively, Track 5 E14.5 MatDi, Track 6 E15.5 MatDi and 
Track 7 E15.5 WT. (C) In some Mat Di muscles fast MyHC 
staining is almost entirely abolished compared (D) to WT 
siblings in which over half of myotubes at this stage contain 
fast MyHC. In the posterior insertional region of the dia-
phragm, the intensity of staining and number of fast MyHC 
positive skeletal myotubes at E15.5 is, (E) decreased in 
maternal disomy mutant embryos (19% fast MyHC positive 
myotubes) compared to (F) litter mate controls (MatDi Con 
38% fast MyHC myotubes). Magnification bars represent 10 
microns.Page 7 of 16
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endogenous Igf-2, similar to levels expressed by undiffer-
entiated C2MIG cells (Fig. 6A). As expected Igf-2 expres-
sion levels are strongly up-regulated in C2MIG cells
during differentiation as the MIG transgene is switched
on. Weak induction of Igf-2 in differentiated C2MG cells
is due to the presence of small numbers of Igf-2 positive
myotubes in these cells. Using semi-quantitative RT-PCR
for Gfp we show that Gfp message is detectable only in
differentiated C2MG and C2MIG cells and is abolished in
cells transfected with pShagGfp but not those expressing
pShagIgf-2 (Fig. 6B). Densitometry analysis demonstrates
that both endogenous and MIG generated Igf-2 message
are effectively suppressed in cells transfected with pSha-
gIgf-2 demonstrating ShRNA knockdown close to 100%.
Igf-2 message is not affected in cells transfected with an
RNAi construct targeting Gfp (pShagGfp) (Fig. 6A, C).
ShRNA knockdown of Igf-2 abolished the shift towards
fast-myosin myotube production seen in C2MIG cells
(Fig. 6D). C2MIG cells transfected with pShagIgf-2 display
a 50% decrease in the proportion of fast myosin positive
myotubes and a 30% increase in the proportion of slow
myosin positive myotubes compared to pShagGfp (or
control C2MIG) transfected myotubes, suggesting that a
majority of the excess fast myotubes generated by C2MIG
cells (shown in Fig. 3) are made at the expense of generat-
ing slow myosin containing myotubes (Fig. 6D–E).
ShRNA knockdown of endogenous Igf-2 in C2MG cells
resulted in a 15–20% reduction in the proportion of
FMyHC+ myotubes compared to control C2MG or pShag-
Gfp transfected C2MG cells demonstrating that endog-
enous Igf-2 plays a role in the generation of fast myotubes
(Fig. 6D). Interestingly, there was no statistically signifi-
cant effect on the proportion of slow-myosin positive
fibres present in these cultures suggesting that loss of
endogenous Igf-2 expression alone is insufficient for the
promotion of slow twitch myotubes under WT condi-
tions. Loss of Igf-2 protein, in Igf-2 ShRNA treated C2MIG
cells, is shown in Fig. 6F. In these cultures myotubes are
formed but do not express Igf-2 (Fig. 6F, black arrow).
The timing of mCK expression in C2MIG cells coincides
with the appearance of endogenous Igf-2 in wild-type
skeletal muscle myoblasts (Fig. 6G). As in wild-type
C2C12 (and C2MG) cells Igf-2 protein is not present in
proliferating cells but can be first detected in a small
number of cells with bipolar morphology around 24
hours after switching them into differentiation permissive
medium (2% horse serum) (white arrow Fig. 6G). By 3
days in differentiation medium fully formed multinucle-
ate, Igf-2 positive myotubes can also be identified (Fig.
6G, black arrow). Interestingly in clonally derived WT
myoblast cultures, only about half of myotubes formed in
culture under differentiating conditions contain Igf-2 and
Igf-2 negative myotubes can also be identified. The pres-
Semi-quantitative RT-PCR for (A) Igf-2 and (B) Gfp C2MG and C2MIG cells transfected with RNAi constructs respectively targeting Igf-2 (pShagIgf-2, Ii) and Gfp (pShagGfp, Gi)Figure 6
Semi-quantitative RT-PCR for (A) Igf-2 and (B) Gfp C2MG and 
C2MIG cells transfected with RNAi constructs respectively 
targeting Igf-2 (pShagIgf-2, Ii) and Gfp (pShagGfp, Gi). (C) Den-
sitometry of Igf-2 signal expressed as a ratio of α-tubulin con-
trols confirms that pShagIgf-2 (Ii) but not pShagGfp (Gi) 
abolishes the Igf-2 message (* statistically significant, p < 0.05, 
Student t-test). (A, C) Endogenous Igf-2 mRNA is detected at 
very low levels in undifferentiated (Un) wild-type (C2MG) and 
C2MIG cells and is upregulated following differentiation (Di). 
Substantial induction of ectopic Igf-2 mRNA is seen in C2MIG 
expressing cells following differentiation. pShagIgf-2 abolishes 
both endogenous and ectopic (C2MIG) Igf-2 mRNAs. (B, C) 
Gfp mRNA is not present in undifferentiated C2MG or C2MIG 
cells but is detected in both cell lines following differentiation. 
pShagGfp abolishes Gfp mRNA in these cells. (D) C2MIG cells 
transfected with pShagIgf-2 show a substantial reduction in the 
proportion of their fast-myosin positive myotubes which is sta-
tistically significant (Student t-test, p = 0.004, indicated by **) 
and, (D) a concomitant increase in the proportion of slow 
myosin positive myotubes (statistically significant, P = 0.07 *). 
Abolishing endogenous Igf-2 expression in C2MG cells results 
in, (D) a smaller but statistically significant (p = 0.02, **) drop 
in the number of fast-myosin positive myotubes but (D) does 
not increase the number of slow-myosin positive myotubes. 
Abolishing Gfp using pShagGfp has no effect on the proportion 
of (D) FMyHC or (D) SMyHC positive myotubes present in 
either C2MG or C2MIG cells. Igf-2 RNAi abolishes Igf-2 immu-
nostaining in (F) C2MIG myotubes. (G) Igf-2 is strongly 
expressed in differentiated C2MIG myotubes (F-G; black 
arrows indicate myotubes). (G) Igf-2 is present in small num-
bers of mono-nuclear bipolar cells consistent with the 
reported expression of muscle Creatine Kinase (mCK) just 
prior to differentiation (white arrow). Total myotube number 
for cells treated with lipofectamine, pShagGfp and pShagIgf-2 
was analysed by ANOVA and showed that the number of 
myotubes generated was not affected by the treatment regime, 
p = 0.64 (MG), p = 0.23 (MIG).Page 8 of 16
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myotubes, models that seen in the embryo during late sec-
ondary myogenesis (Fig. 1).
Discussion
In this study we show for the first time that Igf-2 protein
localises to skeletal muscle myotubes during secondary
myogenesis and that it is specifically and progressively
associated with the fast-myosin positive secondary myo-
tube population during the late growth and maturation
phases of embryonic myogenesis. The Igf-2 localisation
pattern largely coincides with the previously reported
mRNA expression pattern for this growth factor
[21,23,24], but the increased resolution afforded by
immunostaining demonstrates the localisation of Igf-2 to
embryonic muscle more precisely and shows that it is
restricted to a subset of myotubes during secondary myo-
genesis. The close correlation between the protein and
mRNA expression patterns suggests that this growth factor
acts in a predominantly cell autonomous (autocrine)
manner in these myotubes. The Igf-2R, a negative regula-
tor of secreted Igf-2, which plays an important role in reg-
ulating embryonic levels of systemic Igf-2 is extensively
expressed in embryonic skeletal muscle, and thus may
contribute to the regulation of this process [32].
Igf-2 localisation specifies the fast twitch motor unit during 
secondary myogenesis
Igf-2 protein localises to embryonic muscle myotubes
later (E13.5) than FMyHC (E11.5) and is also down-regu-
lated earlier (E17.5 compared to P1 for FMyHC) preclud-
ing a role for Igf-2 in the initiation of secondary myotube
differentiation. This conclusion is supported by the find-
ing that in Igf-2 deficient (MatDi) embryos, whilst the
FMyHC+ myotube population is diminished, it is not
absent and myogenesis is not impaired. The localisation
pattern of Igf-2 in embryonic myotubes during late sec-
ondary myogenesis correlates well with the transition
from developmental to mature myosin expression, the so-
called 'late transition window' described by several
authors [6]. Its close correlation with FMyHC expression
suggests a particular role for Igf-2 in establishing the fast
twitch myotube component of these muscles. Like
FMyHC, Igf-2 is predominantly found in secondary myo-
tubes in the early stages of secondary myogenesis
although it shows a more restricted pattern than does
FMyHC. By late myogenesis (E15.5) Igf-2, like FMyHC, is
localised to ~50% of embryonic myotubes and there is a
striking coincidence in the localisation patterns of the two
proteins, both of which are found in (presumptive fast
twitch) motor units (grouped primary and secondary
fibres) which in a majority of muscles are evenly inter-
spaced with FMyHC and Igf-2 negative motor units. This
pattern is widespread (though not uniform) throughout
the hypaxial and epaxial musculature but is particularly
striking in fast and mixed-fibre embryonic muscle groups
such as the Deltoid, Intercostals and Diaphragm. By E17.5
the intensity of FMyHC staining in WT embryonic muscle
is heterogeneous with stronger staining being found in
Igf-2 positive myotubes and staining intensity varies con-
siderably from muscle to muscle. The mixed pattern of Igf-
2 positive and negative myotube clusters present in WT
embryos from E15.5 seems to be required to maintain this
heterogeneity of staining intensity since when Igf-2 is
expressed in all embryonic myotubes (as in MIG
embryos) this variation is lost and FMyHC staining is gen-
erally uniformly intense in all muscles and in individual
myotubes. When Igf-2 is lost (as in MatDi embryos) the
converse is true and FMyHC staining is weaker through-
out the entire musculature.
Disruption of Igf-2 expression causes a shift in the 
FMyHC+ myotube population
In Igf-2 deficient embryos (MatDi) the proportion of
FMyHC+ myotubes in embryonic muscles is halved at
E15.5 although secondary myogenesis is not impaired.
The presence of more weakly staining fast MyHC fibres in
MatDi embryos at E14.5 and the subsequent decline in
the proportion of FMyHC+ myotubes in MatDi embryos
at E15.5 supports our conclusion from the immunostain-
ing pattern of Igf-2 that Igf-2 is not necessary for the for-
mation of fast secondary myotubes but supports the
hypothesis that Igf-2 is required for the continued main-
tenance of FMyHC+ myotubes or conversion of subse-
quent myotubes into fast-twitch fibres. This argument is
also supported by the finding that when Igf-2 is over-
expressed (in MIG mice) the proportion of FMyHC myo-
tubes is increased such that by E17.5 almost 100% of MIG
myotubes contain strong FMyHC staining. Expression of
MIG in vivo causes a substantial shift in the proportion of
FMyHC+ myotubes in embryonic muscles as well as in the
intensity of staining suggesting that Igf-2 may directly
induce FMyHC. Thus by manipulating Igf-2 expression in
late gestation secondary myotubes it is possible to sub-
stantially alter both the proportion and intensity of
expression of FMyHC in embryonic myotubes in vivo.
In addition to Igf-2, there are a number of imprinted
genes contained within the duplicated region of the distal
tip of chromosome 7 in MatDi mice [29]. A majority of
these are not imprinted and/or not expressed in embry-
onic skeletal muscles. Mash-2 and Ins-2 for example, are
imprinted only in extraembryonic tissues and play roles in
placental function, they are unlikely to influence the
reduced FMyHC+ myotube phenotype described here. In
addition to Igf-2, two genes (H19, cdkn1c) are known to
express in skeletal muscle, both are maternally imprinted
and thus up-regulated in MatDi embryos. The net effect of
maternal duplication in embryonic skeletal muscle is
therefore the complete suppression of Igf-2 and its down-Page 9 of 16
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tively regulates Igf-2 at the mRNA level and is unlikely to
influence the muscle phenotype of these mice other than
through the suppression of Igf-2 expression. The cyclin-
dependent kinase inhibitor, cdkn1 (p57kip2) is negatively
regulated by Igf-2 [33]. It is expressed in skeletal muscle
and so may mediate the Igf-2 signal in this tissue [33,34].
Mice lacking both Cdkn1 and p21, but not cdkn1 alone,
have a muscle phenotype and cdkn1 may thus have a role
in myotube differentiation, over-expression of cdkn1 (as
in MatDi) is not however, reported to affect muscle func-
tion [35]. Taken together with our remaining data, the
suppression of FMyHC myotubes in MatDi muscles is
most likely attributable to the absence of Igf-2 rather than
to the over-expression of Cdkn1.
By forcing Igf-2 expression into more myotubes in vitro,
we alter the proportion of FMyHC positive myotubes gen-
erated by cultured myoblasts. In vivo, forcing Igf-2 expres-
sion into all myotubes both increases the proportion of
FMyHC positive fibres and abolishes the heterogeneity of
FMyHC staining which is established in late gestation
(E17.5) embryos. Igf-2 therefore appears to be necessary
for controlling the number of fast myotubes formed
throughout the musculature and may play a crucial role in
the mechanism of fibre-type switching which establishes
the correct proportion of fast and slow twitch fibres in
each individual muscle group.
Igf-2 regulates the post-natal FMyHC pattern
Both Igf-2 and fast-myosin are previously reported to sub-
stantially down-regulate in mice at birth [6,36]. Our data
demonstrates that Igf-2 and FMyHC are sequentially sup-
pressed at the end of myogenesis with Igf-2 downregula-
tion preceding that of FMyHC. By E17.5, in wild type (and
MG) embryos, Igf-2 is almost entirely absent from embry-
onic muscle and FMyHC staining is less intense in some
myotubes (compared to E15.5). By birth, consistent with
previous reports, both proteins are strongly suppressed.
MIG induces a generalised increase in the intensity of fast
MyHC staining and in the number of fast MyHC positive
myotubes in embryonic skeletal muscles. MIG causes a
very striking elevation of fast MyHC staining in embry-
onic myotubes at E17.5 in comparison to MG. When Igf-
2 is prevented from down-regulation at E17.5 (as in MIG
embryos) FMyHC also fails to down-regulate, resulting in
a substantial increase in FMyHC+ myotubes at E17.5 and
a very substantial excess of FMyHC+ muscle fibres in P1
neonates. These data strongly indicate a role for Igf-2 in
the specification of the FMyHC+ myotube.
In vertebrates a focus of recent research has been the role
of innervation in determining skeletal muscle fibre type
post-natally. Depending on species and the skeletal mus-
cle examined, experimental deinnervation of adult mam-
malian skeletal muscles has been shown to cause a shift in
fibre type expression from fast to slow or from slow to fast
myosin fibre types [8,37]. It is also possible to modulate
slow and fast myosin expression patterns in post-natal
muscles by loading and unloading muscles by means of
exercise or forced inactivity respectively [38]. In some of
these studies growth factor expression changes have been
reported and both Calcineurin and NFATc3 signalling
have been shown to mediate fibre switching (towards
slow MyHC) in response to neural and loading cues sug-
gesting that growth factor signalling may mediate post-
natal switches in myosin type induced both by innerva-
tion and mechanical load [39-41]. Igf-2 is the first growth
factor which promotes fast myosin expression in embry-
onic muscle fibres.
Igf-1, a growth factor which is closely related to Igf-2 but
with distinct function and regulatory pathways in embry-
ogenesis, induces a very substantial myotube hypertrophy
when over-expressed in embryonic myotubes [42]. Igf-2
does not appear to induce this same effect and we found
no evidence of hypertrophy in MIG embryos, neonates or
cultured MIG myotubes. Similarly, in neither MatDi nor
Igf-2 ShRNA transfected myotubes did we see a reduction
in the diameter of myotubes compared to WT or untreated
myotubes. This is consistent with a large body of data
which suggest that the two growth factors have distinct
roles in embryogenesis [13,22,24,43]. Detailed analysis of
the respective roles of Igf-1 and Igf-2 in the embryonic
nervous system and preimplantation development sup-
port this view and suggest that Igf-2 signalling may require
the Igf type 2R (Igf-2R) in early embryogenesis [22,44].
Unlike Igf-2, Igf-1 is not expressed in embryonic skeletal
muscle, although it is present in non-muscle mesenchy-
mal cells and embryonic neural tissues. The Igf type 1
receptor (type 1R) is more widely expressed and can medi-
ate signal of both peptides in many tissues, however data
from phenotypes of Igf axis null embryos suggests that
both function and signalling of the two peptides in the
embryo is distinct. This is especially true in late embryo-
genesis (coincident with secondary myogenesis) when Igf-
2 function does not depend on the type 1R but instead
acts via alternative receptors such as the Insulin receptor
(InsR) or hybrid receptors [24,43,45,46]. Igf-2 function is
also extensively regulated by the Igf-2R [32,47]. Both Igf-
2 and Igf-2R expression are regulated by genomic imprint-
ing.
Medical implications
The regulation of fibre-type is of importance to the eluci-
dation and treatment of Duchenne skeletal muscle dystro-
phy which shows preferential destruction of type 2 fibres
resulting in the rapid loss of function of fast and mixed
fibre muscles of the limb and trunk and in destruction of
the fast-fibre component of the respiratory (intercostalsPage 10 of 16
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particular in which we report altered Igf-2 expression to
have its most substantial effect on the embryonic and
perinatal fast twitch myotube population. Detailed analy-
sis of individual muscles in MIG+ mice revealed both an
increase in the intensity of fast-myosin staining compared
to wild type as well as an increase in the proportion of
fibres retaining fast-myosin. Whilst this difference was
most striking in muscle groups such as the Deltoid and
Trapezius which are destined to become mixed fibre mus-
cles, there was also a shift towards FMyHC positive fibres
in the diaphragm and intercostal muscles. In the human
and rodent adult these specialised respiratory muscles
have a finely balanced composition which ranges between
40–50% Type 1 (slow myosin) and 50–60% Type 2 (fast
myosin) which is essential for their role in respiration
[49,50]. Whilst MIG mice do not have respiratory difficul-
ties at birth, the increase of Type 2 myosin in their respi-
ratory muscles may have long term consequences on the
stamina or adaptability of their diaphragmatic and inter-
costal muscles.
Some growth factors including Igf-2 and growth hormone
have been demonstrated to exert an ameliorative effect on
the juvenile dystrophic phenotype in the mdx mouse (a
genetic model for DMD). This suggests that dystrophic
fast-twitch muscle fibres could be particularly vulnerable
to the rapid down regulation of Igf-2 which takes place at
birth in both mouse and human and may benefit from
supplementary post-natal Igf-2, providing an important
therapeutic approach for this severe and intractable dis-
ease [27,51]. In DMD, children usually die from respira-
tory failure associated with loss of function of the
respiratory muscles. Growth hormone (GH) has been
shown to improve tensile strength in mdx diaphragm,
whilst Igf-1 inhibits myofibre breakdown in mixed fibre
muscles such as the quadriceps although not in the dia-
phragm [51,52]. Here we show that it is possible to regu-
late the production of fast twitch fibres by manipulating
the expression of Igf-2 in vivo or in cultured myotubes.
The respiratory muscles appear to be particularly sensitive
to Igf-2 expression levels and Igf-2 promotes fast fibre pro-
duction in these muscles in both embryonic and post-
natal intercostal and diaphragmatic muscles suggesting
that Igf-2 may be particularly useful in therapeutic strate-
gies targeting the respiratory muscles.
Conclusion
Igf-2 localises to ~50% of myotubes during a narrow time
window in late secondary myogenesis coinciding with
embryonic fibre-type transition, and is required for estab-
lishing the correct proportion of fast twitch motor units in
embryonic and neonatal muscle groups.
Methods
Preparation of mouse embryo samples
Mouse pairs were established as natural matings to gener-
ate embryonic stages E10.5 to E17.5 (morning of plug
detection counted as E0.5). Pregnant females were culled
by cervical dislocation (in accordance to Schedule I
method of the Animal (Scientific Procedures) Act 1986).
Maternal disomy chromosome 7 (MatDi) embryos and
their wild type (WT) litter mate siblings (obtained from
Anne Ferguson Smith, University of Cambridge, UK) were
produced by intercrossing mice carrying stable robertso-
nian translocations as described previously in [34,53].
Embryos from mixed MatDi and WT litters were fixed and
subsequently stained in parallel. All embryos were fixed in
4% paraformaldehyde (PFA) overnight, followed by sub-
sequent dehydration and embedding in paraffin wax as
previously described [27,34]. All sections were sagital
(5μm).
Immunohistochemical (IHC) detection of Igf-2 and myosin 
subtypes
Embryo and P1 pup sections were de-waxed and dehy-
drated before being subjected to an appropriate antigen
retrieval method (Phem Triton for 2 minutes or 2 minutes
high pressure immersion in hot sodium citrate buffer; pH
6.0), as described previously [34]. Endogenous peroxidase
was blocked using hydrogen peroxide, (3% H2O2 in water
and 0.5% H2O2 in Methanol), slides washed and then
blocked in 3% BSA in phosphate buffered saline (PBS) for
anti-Igf-2 or 3% Milk in PBS (all myosin antibodies), or
TNB buffer (for tyramide signal amplification). Adjacent
sections were incubated overnight at 4°C in primary anti-
bodies; anti-Igf-2 mouse monoclonal IgG1 (1/100,
Upstate Biotechnologies); anti-skeletal myosin (fast) IgG1
(1/1000, Sigma, Clone MY32); anti-pan myosin (1/1000,
MF20); anti-slow myosin mouse monoclonal (1/100,
A4.840) and anti-Pax 7 (1/500) all from Developmental
Hybridoma Studies Bank (DHSB), Iowa City); anti-GFP
(1/1000, MBL); antibody concentrations established by
titration) or (secondary antibody control) in diluent (1%
blocking buffer) alone. Secondary goat-anti-mouse bioti-
nylated antibody (1/1000 in 1% blocking buffer, Amer-
sham Life Sciences) was incubated at 20°C for 1 hour.
Visualisation was achieved using either vector ELITE ABC
detection (Vector Laboratories Ltd) or tyramide signal
amplification (TSA: PerkinElmer Life Sciences) followed
by 1mg/ml 3,3' diaminobenzidine tetrahydrochloride
(DAB Dako Ltd). Embryos were counterstained with Gill's
Haematoxylin (BDH, UK) using standard protocols.
Where sections are compared in figures the same protocol
was used for each section and antibody (see figure leg-
ends). Cell lines were immunostained using the same pro-
tocols (analysis is described below).Page 11 of 16
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The specificity of the Igf-2 primary antibody (upstate Bio-
technologies) was established by pre-incubation of the
antibody with 2g/ml Igf-2 (Growpep) for 1 hour at room
temperature. Pre-absorbed antibody was used in the
immunstaining procedure as described above. Pre-
absorption of the anti-Igf-2 antibody with 2μg/ml Igf-2
peptide completely abolished Igf-2 immunostaining in all
regions where signal was obtained, shown here for both
embryonic liver and diaphragm (Fig. 2 A-B). The pattern
of immunolocalisation of Igf-2 broadly followed that
published for mRNA in situ [24,54,55,36] and showed
Igf-2 to be distributed widely throughout the developing
embryo in a range of tissues including omphalocoele,
skeletal muscle, brain, liver, kidney, heart, gut and devel-
oping bone (to be published elsewhere). During the sec-
ond half of gestation a predominant site of Igf-2
localisation is developing skeletal muscle (see Figure 2).
The antibody used to detect fast myosin isoforms in this
study is a monoclonal antibody My32. This antibody is
reported to detect all three fast myosin isoforms (2a, 2b
and 2x/d) but not recognise developmental or cardiac
myosin isoforms. Cross-reactivity with neonatal MyHC
has been reported for this antibody in rat [56] although
neonatal myosin was not formally identified in this study.
To establish the specificity of the anti-FMyHC (clone
My32) antibody whole embryo proteins were electro-
phoresed in duplicate on 7.5% SDS-PAGE to allow sepa-
ration of myosin isoforms and immunoblotted for
FMyHC and Neonatal MyHC (WB-MHCn) (half the blot
for each antibody). Anti-spectrin was used as an internal
marker (Figure 2C–D). From E13.5, My32 detects three
bands corresponding to adult type 2a, 2x and 2b which
increase substantially in intensity from E15.5 showing
that in mouse, My32 predominantly detects all three adult
FMyHC isoforms. A band which co-runs with FMyHC 2a,
but does not increase with embryonic stage, is detected by
WB-MHCn. This is likely to be a neonatal MyHC but may
be cross-reactivity with FMyHC 2a since this antibody also
weakly detects the Adult MyHC in the marker track.
Data analysis of Immunostaining and histological sections
Immunostaining patterns were established using a mini-
mum of three separate staining runs per embryo and a
mimimum of three separate embryos for each stage and
strain. In many cases many more sections were stained.
For the direct comparison of fast myosin and Igf-2 pat-
terns, staining for both antibodies was carried out on care-
fully matched adjacent sections and repeated 3 or 4 times.
Quantitation of fast myosin staining in wild type and
mutant embryos and in neonatal skeletal muscles was
achieved by assessing the intensity of staining (strong,
weak or absent) in muscle fibres and by counting the
number of myotubes in which staining was present in
embryos and P1 pups). Only non-adjacent transversely
sectioned muscle fibres were included in this analysis. At
least 3000 fibres were counted for each data point and
material from different embryos and different staining
runs were included in the analysis to exclude experimental
bias. Statistical analysis of these data was by Student t-test
and ANOVA as indicated in the figure legends.
Construction of MIG and MG transgenes
A bicistronic transgene (MIG, mCK-Igf-2- IRES2-EGFP)
expressing insulin-like growth factor 2 (Igf-2) and green
fluorescent protein (eGFP) from a muscle specific pro-
moter (muscle creatine kinase, pmCK) and a control
transgene (MG, mCK-IRES2-EGFP) expressing eGFP alone
were constructed using a two stage process using a com-
mercially obtained CMVpIRES-eGFP vector (pIRES2-
EGFP, Clontech), p99a:5, a vector containing the coding
region of Igf-2 (exons 4,5,6) (gift from Andrew Ward, Uni-
versity of Bath, UK [57]), and a full length muscle Creat-
ine Kinase promoter containing vector (p3300MCKCAT)
(a gift from Jean Buskin and Steve Hauschka, Seattle, USA
[58]). The full length (p3300MCKCAT) promoter con-
tains all three mCK regulatory elements and has been
demonstrated to be equally expressed in all muscle fibre
types [59]. To obtain MIG pIRES-EGFP (pIRES2-EGFP)
was digested with AseI-XhoI to remove the CMV promoter
(pIRES2-EGFP(-)) which, following modification of
digested ends, was ligated sequentially with Igf2 (p99a:5)
and the mCK promoter (p3300MCKCAT) via an interme-
diate construct pIGF2-IRES2-EGFP, to generate MIG. To
generate the the control construct MG, the mCK promoter
(p3300MCKCAT) was excised and ligated with a PstI-
XmaI digestion of pIRES-EGFP (-). Plasmids with inserts
were extensively characterised by restriction endonucle-
ases mapping and DNA sequencing before transfection
into skeletal muscle cells.
Generation of MIG transgenic mice
MIG transgenic mice were generated by pronuclear injec-
tion. The transgene was removed from the vector by
sequential digestion with EcoR1 and BspH1 followed by a
Quiagen purification step. This fragment was microin-
jected into fertilized one-cell mouse embryos, derived
from CBA × C57BL10 F1 matings. The embryos were
implanted into CD1 pseudopregnant female mice. Previ-
ous attempts to generate MIG transgenic mice on
C57BL10 and DBA × C57BL10 backgrounds resulted in
very low numbers of MIG positive mice reaching term and
all died within the first few days. These pups were fixed
and characterised in comparison with their transgene neg-
ative littermates and with MG transgene positive pups to
generate the data shown in Figure 4. All of these mice were
morphologically normal and of the same size as their
transgene negative siblings. To establish whether some of
these animals were dying in utero we culled litters of MIG
or MG injected embryos at E11.5, E13.5, E15.5 and E17.5Page 12 of 16
(page number not for citation purposes)
BMC Developmental Biology 2007, 7:65 http://www.biomedcentral.com/1471-213X/7/65and compared litter size, resorption rate and transgene
positivity between MIG and MG. Three litters were exam-
ined for each stage comprising a total of 117 (MG) and
120 (MIG) embryos. Litter size did not change with stage
and was not significantly different between MIG and MG
injected embryos (MIG 10 + 2.7; MG 9.75 + 1.4, not sig-
nificantly different by Student t-test, p = 0.83). Resorption
rate was also the same for both MG and MIG and did not
alter with stage (MIG 3.25 + 0.45; MG 4 + 1.28, p = 0.36).
The proportion of transgene positive animals generated
was around 10% for both transgenes (MG 10.2%; MIG
9.3%). When allowed to reach full term, MIG mice are
morphologically normal and do not exhibit respiratory
difficulties at birth; however a majority die within the first
few days probably through a failure to suckle. Recently we
successfully fostered MIG + pups which survive, a more
detailed characterisation of these mice will be published
elsewhere. For genotyping, genomic DNA was isolated
from placenta (embryos) or tail clips (P1 pups) and PCR
carried out to amplify the fragment at the mCK and IGF2
junction (see Figure 2F). Transgene positive animals were
then characterised using six different primers: mCKIgf-2 1
and 2 (across the mCK promoter and Igf-2 junction), Igf-
2IRES 1 and 2 (across the Igf-2 and IRES junction) and
GFP specific primers (MIGGFP 1 and 2).
Primer sequence mCKIgf-2 1 (shown in Figure 3)
Forward: 5'- CTCCTCTATATAACCCAGGGGCAC-3'
Reverse: 5'- CCCCAACTGGGAAATCAAGAGAAG-3'
As a control MG transgenic mice were generated using the
same procedure. For genotyping of these mice primers
spanning the mCK-IRES junction (mCKIRES 1 and 2) and
GFP-plasmid junction (MGGfp) were employed. These
mice are viable and morphologically normal. The GFP
expression pattern of both MG and MIG is consistent with
previous reports for the full length muscle creatine kinase
promoter (mCK) expression [57] and both transgenes are
expressed in all muscle myotubes (see Figure 4A).
Generation of C2MIG and C2MG myoblast cell lines
mCK-IGF2-IRES-gfp (MIG) and mCK-IRES-gfp (MG) con-
structs were transfected into C2C12 cell lines using
Lipofectamine2000 (Invitrogen) followed by G418 selec-
tion. Single cell derived clones were then isolated and
characterised for expression of the transgene (for methods
refer to [60]. Two representative clones, C2MIG (H12)
and C2MG (B9) were used throughout this study.
Cell Culture and differentiation of C2MIG and C2MG cells
C2MIG and C2MG cells were plated out (1 × 104 cells/ml)
into 8 well chamber slides (Nunc) and cultured for 24
hours in Dulbecco's Modified Essential Medium (DMEM,
Gibco) supplemented with 10% Fetal Calf Serum (batch
tested FCS; Sigma) before transferring either into differen-
tiation medium (DMEM supplemented with 2% Horse
Serum (batch tested HS; Sigma) or to fresh DMEM supple-
mented with 10% FCS. Cells were differentiated for 3
days. Differentiated cells were then fixed in 4% PFA and
processed for immunohistochemistry (IHC) as described
above. Each experiment presented was replicated out on 3
separate occasions and all experiments were carried out in
duplicate. For each well 16 representative grid areas were
counted per well (i.e. per replicate), representing a mini-
mum of 2000 myoblasts per replicate. When cultured
under these conditions, statistically, there was no differ-
ence in the total number of myotubes produced by
C2MIG (H19) cells (15.3 ± 3.7 myotubes) per grid com-
pared to C2MG (B9) (13.0 ± 2.8 myotubes per grid); no
significant difference, Student t test, p = 0.47.
Plating efficiency analysis was carried out by plating cells
(C2MG or C2MIG) at a density of 104 cells/90 cm dish fol-
lowed by incubation for 6 hours and fixation and staining
in Leishman's methanol stain (see [31], for method).
Cloning analysis was carried out by plating cells at 103/
plate and incubating for 5 days before fixation and stain-
ing in Leishmans'stain as before. Plating efficiency and
colony formation assays carried out on C2MG (B9) and
C2MIG (H19) cells showed no significant difference
between the two lines (Student t test: p = 0.23 and p = 0.60
respectively).
ShRNA Interference
Constructs
ShRNA constructs were generated against Gfp (RNAi-Gfp)
and Igf-2 (RNAi-Igf-2) respectively using the pSHAG RNAi
vector system described by [61]. Unique 29bp hairpin
sequences were inserted into a HIND III site in the pSHAG
vector. A Not1 site is located upstream of the U6 promoter
region. ShRNAi inserts could therefore be detected by the
presence of a larger plasmid band following Hind111
digestion of the construct. The presence of the ShRNA
insert was confirmed by a double restriction enzyme
digest using HIND111 and Not1. Sequences for the Gfp
and Igf-2 RNAi inserts were as follows:
Forward: RNAi eGFP: 5'-AAC TTC AGG GTC TAG GTG
GGA AGC TTG CTA CTT ATG GCA AGC TGA CTC TGA
AGT TCA TTT TTT T-3'
Reverse: RNAi eGFP: 5'-GAT CAA AAA AAT GAA CTT
CAG AGT CAG CTT GCC ATA AGT AGC AAG CTT CCC
ACC
Forward: RNAi Igf-2: 5'-CGA CGG TTG GCA CGG CTT
GGA GGC CTT CGA GTC GTG CTA ACC GTC GCA GTT
TTT T-3'Page 13 of 16
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AGC ACG ACT CGA AGG CCT ACC AAG CCT TCA AGC
CGT GCC AAC CGT CGC G-3'
ShRNA Transfection
C2MIG and C2MG skeletal muscle cells were transfected
using an optimized modification of the manufacturers
instructions for use with lipofectamine 2000 (Invitrogen).
Cells were incubated in DNA/lipofectamine 2000 for 24
hours before being plated out at 1x104 cells/ml into
DMEM+10%FCS for 24 hours. Cells were switched into
differentiation medium (DMEM supplemented with 2%
batch tested Horse Serum (Sigma)) for 3 days before being
either fixed in 4% PFA followed by immunohistochemis-
try, or subject to RNA extraction for RT-PCR analysis or
protein extraction for western blotting.
RT-PCR
Verification of Igf-2 RNAi knockdown was achieved by
semi-quantitative RT-PCR ([31] method modified for
non-radioactive detection). Total RNA was extracted from
cell cultures using TRIZOL and following the manufac-
turer's instructions (Gibco; Invitrogen Life Technologies).
First strand cDNA was generated using a SuperScript II
first-strand synthesis system for RT-PCR (Invitrogen Life
Technologies). The linear range of product amplification
was established for each PCR primer set used (Igf-2, GFP
and α-tubulin). An equalisation step was carried out in
which all cDNA's were diluted in series and subject to PCR
for α-tubulin. GFP and Igf-2 were amplified using these
equalised concentrations. For all primer sets amplification
was preceded by one 3 minute cycle at 94°C and con-
cluded with a final extension step at 72°C for 5 minutes.
Annealing temperatures and number of cycles is indicated
below. To ensure detection of Gfp RNA message only,
RNA was prepared as above except that, prior to being
reverse transcribed, it was DNase treated (Invitrogen Life
Technologies) following manufactures guidelines. Results
were visualised by electrophoresis (1% agarose gel),
stained with ethidium bromide and quantified by densit-
ometry.
Igf2 Primers (31 cycles; annealing temperature 56°C)
Forward: 5' AGT CGA TGT TGG TGC TTC TC -3'
Reverse: 5' TGA TGG TTG CTG GAC ATC TC - 3'
α-tubulin Primers (19cycles; annealing temperature 55°C)
Forward: 5' AGA TGC CAA GTG ACA AGA CC - 3'
Reverse: 5' AGA TGG CCT CAT TGT CTA CC - 3'
Gfp Primers (22 cycles; annealing temperature 55°C)
Forward: 5' AGG ACG ACG GCA ACT ACA AG - 3'
Reverse: 5' CTG GGT GCT CAG GTA GTG GT - 3'
Protein Preparations and Western Blot Analysis
Whole cell extracts were taken from cells differentiated for
3 days using RIPA buffer and protease inhibitors (Roche)
mix and stored at -80°C. Protein (15 μg) was electro-
phoresed on 10% SDS-PAGE and then transferred to
nitrocellulose membranes (Amersham). ECL detection
(Pierce Endogen Hyclone) was carried out in accordance
to manufactures recommendations. Antibodies used were
as follows: Igf-2 and fast myosin clone My32 (as described
above); α-tubulin IgG1 (1/1000, Sigma); spectrin (1/00,
Novocastra); neonatal myosin (Wb-MHCn 1/250, Novo-
castra) and Goat anti-mouse IgG-HRP (1/2000, Santa
Cruz Biotechnology).
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